Ariad update On Brigatinib

Ariad presented an update on a phase I-II clinical trial. The results are pretty good but confusing.

There are three cohorts of Crizotinib resistant patients. A) 90mg daily ongoing, B) 90mg daily for 7 days then 180mg daily ongoing, and C) 180mg daily ongoing. Their was similar efficacy among the cohorts.

Cohort A

14 evaluable patients,  Objective response rate (ORR) was 79%, median Progression Free Survival (PFS) 12.9 months

Cohort B

26 evaluable patients, ORR was 81%, median PFS not yet been reached

Cohort C

25 evaluable patients, ORR was 68%, median PFS 11.1 months

In a post-hoc analysis of brain MRIs, brigatinib demonstrated intracranial Central Nervous System  antitumor activity in patients.

ORR was 53% in evaluable patients with measurable lesions (greater than 10 mm) (n=15).
In evaluable patients with non-measurable lesions (all lesions less than 10 mm) (n=30), ORR (defined for these results as disappearance of all lesions) was 30%. For patients with a follow-up MRI scan (n=45), median intracranial PFS was 22.3 months.

http://www.onclive.com/web-exclusives/Brigatinib-Achieves-Brain-Metastases-Control-for-Over-80-of-ALK-Positive-NSCLC-Patients

http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2036186

This entry was posted in brigatinib-Alunbrig from Takeda, Research. Bookmark the permalink.

Leave a Reply